Esketamine's Role in Reducing Postoperative Anxiety in Adolescents

Esketamine's Efficacy in Adolescent Surgery

A recent randomized controlled trial published in June 2026 has demonstrated that subanesthetic doses of esketamine can effectively reduce postoperative anxiety in adolescents undergoing surgery. The study, conducted on 92 adolescents aged 13 to 18 years, found significant reductions in anxiety scores in the esketamine group compared to the placebo group on postoperative days 1, 3, 7, and 14. Depression scores showed significant differences only on day 14. These findings suggest that esketamine could serve as a valuable perioperative intervention for psychological distress in this demographic.

Mechanism and Context

Esketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, is known for its analgesic, sedative, antidepressant, and anxiolytic properties. Despite its established use in adult populations, its efficacy and safety in adolescent surgical patients have not been systematically studied until now. The trial utilized a double-blind, placebo-controlled design to assess the impact of a 0.25 mg/kg intravenous dose of esketamine administered at the time of skin incision. In addition to psychological assessments, the study measured inflammatory markers like C-reactive protein (CRP) and interleukin-6 (IL-6), alongside pain evaluations, to provide a comprehensive understanding of esketamine's effects.

Policy and Research Implications

The findings of this study could have significant implications for perioperative care in adolescents. Current interventions for managing postoperative anxiety and depression in this age group are limited, making esketamine a promising candidate for further exploration. However, the study's limitations, including its small sample size and single-center design, underscore the need for larger, multicenter trials to validate these results. Policymakers and healthcare providers may consider integrating esketamine into perioperative protocols, pending further evidence of its efficacy and safety.

Risks and Unknowns

While the trial reported no significant differences in adverse events between the esketamine and placebo groups, the long-term safety profile of esketamine in adolescents remains unclear. The absence of significant changes in inflammatory markers suggests that esketamine's anxiolytic effects may not be mediated by anti-inflammatory mechanisms, raising questions about its precise mode of action. Additional research is needed to explore these aspects and to assess the potential for any long-term cognitive or psychological effects.

Looking Forward

The promising results of this trial pave the way for further investigations into esketamine's role in managing postoperative psychological distress in adolescents. Future studies should aim to include diverse populations and extended follow-up periods to better understand the long-term implications of esketamine use. As the field of psychedelic research continues to evolve, esketamine's potential applications in clinical settings may expand, offering new avenues for improving patient outcomes.